L’Oréal and Walgreens back AI biomaterials start-up

Shenzhen Boyin Biotechnology Chinese biotechnology company Shenzhen Boyin Biotechnology has raised US$27.5 million in Series A and A+ financing. The funding was co-led by L’Oréal’s BOLD investment fund, a fund established by Walgreens and Guangzhou Pharmaceutical, and Guangxin Fund. Founded in 2021, Shenzhen Boyin combines synthetic biology and artificial intelligence to develop biomaterials for beauty, … Read more